Shopping Cart
- Remove All
Your shopping cart is currently empty
BPK-29, a ligand specifically targeting the atypical orphan nuclear receptor NR0B1, disrupts its protein interactions through covalent modification at C274, thereby impairing the anchorage-independent growth of KEAP1-mutant cancer cells.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $1,520 | 1-2 weeks | |
| 50 mg | $1,980 | 1-2 weeks | |
| 100 mg | $2,500 | 1-2 weeks |
| Description | BPK-29, a ligand specifically targeting the atypical orphan nuclear receptor NR0B1, disrupts its protein interactions through covalent modification at C274, thereby impairing the anchorage-independent growth of KEAP1-mutant cancer cells. |
| In vitro | BPK-29 effectively targets NR0B1, demonstrating considerable proteomic selectivity within KEAP1-mutant Non-Small Cell Lung Cancers (NSCLCs)[1]. |
| Molecular Weight | 470 |
| Formula | C26H32ClN3O3 |
| Cas No. | 2143467-62-1 |
| Relative Density. | 1.26 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.